OBJECTIVES-The purpose of this study was to examine the humoral and cellular immune reactivity to adenoviral vector (AdhAQP1) administration in the human parotid gland over the first 42 days of a clinical gene therapy trial.
Introduction
Adenoviral (Ad) vectors have been particularly useful in transferring genes to non-dividing cells, such as the epithelial cells found in salivary glands (Samuni & Baum, 2011) . However, both adenovirus and Ad vectors typically elicit strong immunoreactivity (Jooss & Chirmule, 2003) . Innate immune responses are generally considered to be the single greatest immune barrier limiting Ad vector gene transfer applications, though cell-mediated immunity certainly limits the extent of transgene expression observed (Gregory et al., 2011 , Nayak & Herzog, 2010 . Additionally, since most people have been naturally infected with adenovirus, neutralizing antibodies (NAbs) are often present in their serum, and at high titers (Pine et al., 2011) . However, there does not appear to be a strong relationship between the pre-existing NAb titer and the extent of gene transfer achieved, at least in humans (Campochiaro et al., 2006 , Harvey et al., 2002 .
Recently, we reported using a first generation, serotype 5 Ad (Ad5) vector, AdhAQP1, to transfer the aquaporin-1 cDNA to single parotid glands in subjects with salivary hypofunction resulting from radiation therapy during their treatment for a head and neck cancer (Baum et al., 2012) . Five of the eleven individuals enrolled and treated in this study exhibited both objective (increased parotid saliva flow rate) and subjective (e.g., less oral dryness) outcomes during the first 42 days of the study; these five individuals are termed responders in the current report. Interestingly, all four of the subjects who received vector at doses >1×10 6 vector particles/ul parotid infusate showed clinical, radiographic and/or laboratory indicators of inflammation (Baum et al., 2012) . Three of these individuals experienced no benefits from the gene transfer maneuver, i.e., were non-responders (see Baum et al, 2012 ; Table 1 this report), including both individuals administered the highest dose of vector delivered (5.8 ×10 8 vector particles).
Herein, we report humoral and cellular immune responses observed during the first 42-day study period, in all treated subjects, and examine analytes (biomarkers) that could predict response to treatment. Since most of the immune related responses to Ad5 vectors occur within the first few weeks after delivery, we limited the analysis to data derived for each subject during the first 6 weeks after AdhAQP1 delivery to the single parotid gland, i.e., a timeframe identical to that described in Baum et al (2012) . Importantly, we found that four of the five subjects who responded positively to vector administration exhibited some systemic indicators consistent with a modest vectorassociated cell-mediated immune response, i.e., increased cytotoxic lymphocytes (CTLs) and/or increased lymphocyte proliferation. However, there was no statistically significant relationship between a subject's response to gene transfer and the pattern and expression of cytokines released, as measured by cytokine multiplex assays. Additionally, serum neutralizing antibodies (NAbs) in general showed modest change following vector administration over the 42-day study period in all subjects independent of pre-existing titers, and there was no simple relationship between subjects' responses to treatment with their baseline NAb titers.
Materials and Methods

Patients and study design
A Phase I/II clinical trial to test the safety and biologic efficacy of AdhAQP1 administration to a single previously irradiated parotid gland in eleven subjects using an open label, single dose, dose-escalation design was conducted (four dose tiers from 4.8×10 7 to 5.8×10 9 vector particles [vp]/gland, see Table 1 ; http://www.clinicaltrials.gov/ct/show/NCT00372320? order=, registered on September 2, 2006). This study was approved by the National Institute of Dental and Craniofacial Research Institutional Review Board, the United States Recombinant DNA Advisory Committee, the NIH Biosafety Committee, and the United States Food and Drug Administration (IND BB-13,102). Additionally, an independent Data and Safety Monitoring Board approved and monitored the study. Informed consent was obtained from all subjects prior to the initiation of any procedures. All methods were carried out in accordance with the approved guidelines (Baum et al., 2012) . Treated subjects were followed at scheduled intervals. Multiple safety parameters were evaluated and the efficacy of the intervention was assessed by measurements of citrate-stimulated parotid salivary flow rate. Visual analogue scales (Pai et al., 2001) were used for symptom assessment.
Neutralizing antibody assay
For this report all serum NAb assays were performed at SAIC-Frederick in batches done during June-July 2011 (for subjects 19, 25, 40, 50, 73, 99, 103, 105, 118) or December 2011 (for subjects 4 and 116). To measure anti-Ad5 NAbs in the subjects' serum samples we used a previously described assay (Sprangers et al., 2003 , Zheng et al., 2010 . Briefly, this assay measured the ability of serum dilutions to prevent a recombinant Ad5 vector, AdCMVLuc encoding luciferase, from transducing 293 cells (Zheng et al., 2010) . Titers are reported as the dilution of serum that resulted in 50% inhibition of the transduction of 293 cells with AdCMVLuc.
Elispot assay (cytotoxic lymphocytes)
Peripheral blood mononuclear cells (PBMCs) were thawed and rested for 2 hours in the presence of 30U/mL of DNase (10,000U/mL, Roche Cat# 04716728001) in 5% HuAB ELISPOT media containing RPMI 1640 (Invitrogen, Cat #21807), 25mM Hepes (Invitrogen, Cat# 15630-080), 1X Pen/Strep-L-glutamine (100X Gibco BRL, Cat#10378-016), and 5% human AB serum (Gemini Cat#100-512). Cells were washed 2 times, counted on Coulter Z1, viability determined by trypan blue exclusion and adjusted to a viable cell count of 3 × 10 6 /ml in 5% HuAB ELISPOT media. ELISPOT opaque plates (Millipore, MSIPS40W10) were precoated with 1μg/well of capture antibody (anti-human IFN-γ mAb 1-D1K; Mabtech, Inc., Cincinnati, OH Cat #3420-3-1000) the previous day. The day of the assay the plates were washed 4 times and blocked with assay media for 2 hours. The blocking media was discarded and PBMCs were plated at 3 × 10 5 cells/well in triplicate. PBMCs were stimulated with 1 mg/ml 293 cell lysate prepared from cells transduced with the AdhAQP1 vector. A lysate from non-transduced 293 cells was used as a non-specific control and stimulation with phytohemagglutinin (PHA) was a positive control for T-cell responsiveness. The 293 cell lysates (± AdhAQP1 transduction) were prepared as follows. Confluent 293 cells, grown in 15 cm culture dishes, were scraped into 20 ml culture media/dish. Cells were centrifuged at 2000 rpm and the media removed. The cell pellet was washed 3-times with phosphate buffered saline (PBS) via re-suspension and re-centrifugation. Thereafter, 2.5 ml 1mM NaHCO 3 was added to pellets from each 15 cm dish, the pellets re-suspended, and the re-suspension subjected to three rounds of freezing and thawing, followed by vortexing. This crude lysate was then centrifuged at 6000xg for 10 min at 4°C, the supernatant removed and PBS added to the original volume (equivalent to 2.5 ml/pellet) and this extract was used as the lysate for ELISPOT assays. For the AdhAQP1-transduced 293 cells we used 50 × 15 cm dishes and this procedure led to a yield of 612 mg protein (5.1 ug/ul), while for the nontransduced 293 cells this procedure yielded 775 mg protein (6.2 ug/ul) from 70 × 15 cm dishes.
After overnight incubation at 37°C in 5% CO 2 , the plates were washed 6x with 0.05% Tween in Dulbecco's PBS to wash the cells and remove the cellular debris. The plates were incubated 2 hours at room temperature with biotinylated IFN-γ antibody (Mabtech #3420-6-100, diluted 1:2000 in PBS/1% bovine serum albumin/0.05% Tween). Thereafter, the plates were washed 4x with Dulbecco's PBS to remove excess antibody. Streptavidinalkaline phosphatase (Mabtech #3310-10, diluted 1:3000 in PBS/1% bovine serum albumin) was added and incubated for 1 hour at room temperature. Spots were visualized by adding 100 μl/well of BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium) (KPL, Cat# 50-81-07 Gaithersburg, MD) for 10 min. for maximal spot development. The reaction was stopped with washing the plates, 3 times, with distilled water and the membranes dried. Spots were enumerated on a CTL-ImmunoSpot ® S5 micro analyzer (Cellular Technology Limited, Shaker Heights, OH). Two frozen normal donor controls with known responsive values were run with each assay to assure quality control of the results. For all assays, at least one of the two controls was within 2 SDs of the lab-generated mean for a pool of T cell epitopes from the human cytomegalovirus, Epstein-Barr virus, and flu viruses used for positive control antigens to elicit responses from antigen-specific memory T cells.
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Lymphocyte proliferation
PBMCs were treated as above and adjusted to a viable cell count of 1 × 10 6 /ml in 10% HuAB Proliferation media containing RPMI 1640, but with the addition of 0.1mM nonessential amino acids (Gibco BRL, Cat#11140-050), 1mM sodium pyruvate (Gibco BRL, Cat#11360-070), 50uM 2-mercaptoethanol (Sigma, Cat#M7522) to that described above, with 10%, versus 5%, human AB serum. PBMCs were then plated into 96-well round bottom polystyrene plates at 10 5 cells/well in triplicate. The plated PBMCs were stimulated as described by Harvey et al (Harvey et al., 1999a , Harvey et al., 2001 with 2.5μg protein/ml Ad5 vector (AdMLPα1AT; (Mastrangeli et al., 1994 , Rosenfeld et al., 1991 ) for 6 days or with 2.5μg/ml phytohemagglutinin (PHA-P, Sigma, Cat#L0917) for 3 days at 37°C in 5% CO 2 . Cells cultured under similar conditions without any stimulation served as the negative control. After the indicated incubation period, the plates were centrifuged and 75μl of supernatant fluid were harvested from individual triplicate wells, combined and aliquoted into 2 vials. Then, 0.5μCi of [ 3 H]-thymidine (Perkin Elmer, Cat#NET-027) was added to each well and incubated for 4 hours at 37°C in 5% CO 2 and thereafter plates were frozen at −20°C overnight. The plates were thawed, the cells harvested onto filtermats (Perkin-Elmer, Cat#1450-421) and allowed to dry several hours. The filters were then placed into sample bags (Perkin Elmer, Cat#1450-432) containing scintillation fluid (Perkin Elmer, Cat#1205-440) and counted with a Beta Scintillation Counter (MicroBeta Trilux, Perkin-Elmer). Proliferation responses were calculated as a stimulation index (SI), as determined by the mean ratio of antigen-stimulated counts per minute (cpm) over background cpm. Two frozen normal donor controls with known responsive values to PHA at day 3 incubation and pokeweed mitogen at day 6 incubation were run with each assay to assure quality control of the assay results. For all assays, at least one of the two controls was within 2 SDs of the labgenerated means for PHA and pokeweed mitogen.
Cytokine multiplex assay
Cytokines were tested in supernatant fluids collected from the above described lymphocyte proliferation plates using a multiplex Th1/Th2 panel from Meso Scale Discovery (Cat.# K15010B) following the manufacturers instructions. The multiplex is an electrochemiluminescence assay and plates were read on the MSD Sector Imager 6000. Cytokines included in the panel were IFN-g, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, and TNF-α. Each proliferation-derived supernatant sample was tested in duplicate and all samples from a single individual were tested in the same assay along with three internal control samples. When the number of samples exceeded the number that could be tested on a single plate one sample, usually the baseline, was tested on both plates. The standard curve range for the assay was 2.4 pg/ml to 10,000 pg/ml.
Statistical Analysis
To describe changes over time between responders and non-responders, as defined above, subject-specific trajectories were plotted for each analyte for each time-point and coded by responder-status. The mean biomarker levels and 95% confidence intervals were plotted by responder-status at each time point and were compared between responders and nonresponders at each time point separately using a two-sample t-test to determine if (1) there is ever a time point prior to 42 days when the analyte levels are statistically different between the groups and (2) there is an analyte that exhibits statistical difference before the other biomarkers under consideration. A biomarker that satisfies both conditions could potentially be used to predict whether a subject will eventually respond to AdhAQP1 gene therapy. As a sensitivity analysis, median biomarker levels, as opposed to mean levels, were compared because of the presence of outliers among the subjects at various time points. The Wilcoxon test was used to compare median biomarker level between responders and non-responders.
Given the small sample size, the analysis did not account for the varying dose tiers of AdhAQP1 vector assigned to the 11 subjects (the results presented are averages over the 4 different dosing tiers) and ignored the correlation in biomarker measures within subjects over time. The presented results were a split-time analysis rather than modeling longitudinal trajectories over time. Additionally, the results were not adjusted for the multiple tests performed across the measured biomarkers and across time points.
Results and Discussion
Analyses of a Phase I/II clinical trial examining immune responses offer several challenges. First, and most important, the sample size is always small and the confounders multiple. Secondly, human biologic variability is usually large. In general, we used a two-prong approach to analyze the results. Initially, we looked at the humoral and cellular immune responses for differences between all responders and all non-responders, searching for potential "universal" changes that could help us understand or could predict responsiveness. Thereafter, we looked at the individual level searching for patterns that could lead to clinically relevant information and associations.
Neutralizing antibody assay
The Ad5-NAb titers did not change substantially (from zero to ~8-fold) over the first 42 days of the study, irrespective of the vector dose concentrations and responder status ( Fig. 1 ; Table 1 ). For example, three subjects with a baseline serum NAb titer of <1:2 were non responders (40, 73, 116) , while two subjects who had quite high serum NAb titers (103, 118): <1:1024 and <1:8192, respectively, were responders. Of the two individuals showing the greatest elevation in serum NAb titer over the 42-day study period (50 and 105; both 8fold increase, 50 increasing from <1:2 to <1:16 and 105 increasing from <1:32768 to <1:262144), the former was a responder while the latter was not. The significance of these findings is twofold. First, for the local delivery of an Ad5 gene transfer vector in the parotid glands, even the highest dose used herein (5.8×10 9 vp/gland) appeared to not dramatically provoke a systemic humoral immune response, at least in the two subjects treated with that dose. Secondly, the initial serum anti-Ad5 NAb titers observed were not simple predictors of a subject's ability to respond positively to the gene transfer maneuver, something that the inclusion/exclusion criteria for future studies can take into consideration. However, it is important to note that subject 105 did have the highest pre-treatment serum NAb titer (<1:32768) and also experienced the most significant spectrum of inflammatory responses to AdhAQP1 vector delivery (Table 1) . 
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Elispot assay (cytotoxic lymphocytes)
CTLs can be key effector cells in the immune-mediated destruction of virally-infected cells. Therefore, we measured both the frequency and function of antigen specific CTLs with an IFN-γ ELISPOT assay by stimulating PBMCs with 1mg/ml 293 cell lysate prepared from cells transduced with the AdhAQP1 vector (Malyguine et al., 2012) . There were no statistically significant differences in the mean number of activated PBMCs between grouped responders and non-responders in any of the time points measured (Figure 2; supplemental Figure 1 ). However, differences between responders and non-responders were highest on Day 14 and, even if not statistically significant for all the subjects, it may prove to be clinically notable. This timing of the presence of the largest number of CTLs corresponds with data shown in previously published reports in other tissue targets (McKelvey et al., 2004 , Mendell et al., 2015 . Looking at the individual plots (Figure 2; supplemental Figure  1) , three of the non-responders (4, 105, 116) exhibited a quite high elevation (8-10 fold) in the number of activated PBMCs on day 14.
Lymphocyte proliferation
As noted earlier, proliferation responses of PBMCs to the Ad5 antigen were calculated as a SI. Grouping responders and non-responders, a difference in the mean values at Day 14 was observed, although it was not statistically significant ( Figure 3 ; supplemental Figure 2 ). However, along with the IFN-γ Elispot assay differences between responders and nonresponders occurring at the same time point, it appears this result warrants increased attention and, perhaps, suggests the possible benefit of using systemic blockers of inflammation over this period. Looking at the individual plots (Figure 3 ; supplemental Figure 2 ), two of the non-responders (4, 116) exhibited an increase in the SI ≥ 10-fold, while no responder exhibited showed an increase >3-fold in their SI over this study period. Subject 105's SI index did not increase until later and it was ~4-fold, which was similar to its day 42 value.
Cytokine multiplex assay
We also looked for trends or specific pathways that could be identified with the multiplex Th1/Th2cytokine panel, measuring the levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, and TNF-α for the same time points as the other immunoassays. In Figure  4 and supplemental Figure 3 we report the individual changes for each cytokine over time and the median differences between responders and non-responders across the time points.
We used the Wilcoxon test and confidence interval, which are based on the pseudo-median and not the raw median. The descriptive and inferential summaries may appear to be discrepant but in reality they are not. That is, the difference in pseudo-medians may not be the same as the difference in the raw medians, which are usually reported in descriptive summaries. Nevertheless, this is not true for an inferential analysis based on means -the estimate from the two-sample t-test is equal to the difference in raw means based on the groups being compared. In supplemental Figure 3 we show that the pattern of inferential results does not change materially between the median-based (left hand side of the figure) and the mean-based (right side of the figure) . By grouping the subjects as responders and non-responders, as described above, we found no evidence of statistical difference between groups for any of the measured cytokines at any time point (all confidence intervals contained zero). However, for some there was evidence of a trend that failed to reach the level of statistical significance (likely due to the small sample size). This may warrant follow-up studies with larger numbers of subjects.
Even though the inherent limitation of a small sample size in a Phase I/II clinical trial precludes the generation of definitive conclusions, there are three key findings from the present study. First, at the doses employed baseline serum anti-Ad5 NAb titers generally were not predictive of a subject's response to parotid gland administration of AdhAQP1. Some subjects with high pre-existing NAb titers (e.g., 103, 118; 1:1024 and 1:8192, respectively) responded positively to treatment, i.e., vector delivery to glands clearly was not blocked by the high, serum anti-Ad5 NAb titer present, while others with low NAb titers (e.g., 40, 73, 116; 1:2 for all) were non-responders (Table 1) . Furthermore, changes in serum NAb titers following vector administration were relatively small (zero to 8-fold) and generally similar in both responders and non-responders (Figure 1) . Additionally, comparable results were found for anti-Ad5 NAb titers measured in saliva from the targeted parotid gland, although full sample analyses were only available for subjects 50, 99 and 103 (responders) and 73 and 105 (non-responders) and at much lower titers than the serum values (data not shown). All five of these subjects had baseline salivary Ad5-NAb titers of <1:16. Indeed, the very low levels of NAbs present in parotid saliva provide the most likely reason for noninterference of salivary epithelial cell transduction via intraductal cannulation. For four of the five subjects for whom baseline and longitudinal salivary Ad5-NAb analyses were performed, two showed no change through day 42 (50 and 73), while two showed a maximum of a 2-fold increase in titer, i.e., to <1:32 (99 and 103). However, subject #105, who had the highest baseline serum Ad5-NAb titer (<1:32,768) showed a 512-fold increase in salivary anti-Ad5 NAb titer in the targeted gland on day 14, which remained constant through day 42. As noted in Table 1 , this subject also exhibited frank gland inflammation, i.e., a flocculent swelling and high 67 Ga uptake (see also (Baum et al., 2012) , suggesting that the elevated salivary anti-Ad5 NAb titer present likely was due to leakage from serum into the forming saliva.
Doubtless many factors influenced an individual subject's responsiveness to AdhAQP1 delivery in this Phase I/II clinical trial. However, from the present results, albeit with a small number of treated subjects, baseline serum Ad5-NAb titers alone appeared not to be simple predictors of parotid gland responsiveness. Overall, the findings herein regarding serum NAb titers and response to treatment are generally similar to those reported by Harvey et al following Ad5 vector administration clinically to several non-malignant tissues and quite different from results following Ad5 vector administration to naïve laboratory animals (Harvey et al., 1999a,b) .
The next key finding herein was that four of the five subjects who responded positively to vector administration nonetheless exhibited some systemic indicators consistent with a modest vector-associated cell-mediated immune response. In three of five responders (50, 99, 118) there were increases (at peak, 2-3 fold; Figure 2 and supplemental Figure 1 ) in detection of CTLs, assessed by an IFN-γ Elispot assay. Three of six non-responders (4, 105, 116) also exhibited increased reactivity in this assay (Figure 2 and supplemental Figure 1 ), but the fold increases were much greater than found with the responders. These same three non-responders also showed the greatest changes in their parotid gland 67 Ga citrate scans at 24-hours post-vector administration (Table 1 ; (Baum et al., 2012) ; see below). Similarly, in three of five responders (19, 99, 118) there were modest increases in Ad5 antigen-induced PBMC proliferation (at peak, 3 fold; Figure 3 and supplementary. Figure 2 ), while the same three non-responders with an elevated CTL response (4, 105, 116) again showed much greater lymphocyte proliferation levels. For all non-responder subjects, the Elispot and proliferation assay results were consistent with clinical findings ((Baum et al., 2012) ; Table  1 ). Thus, the present data suggest that modest (2-3 fold changes) systemic cell-mediated immune reactivity does not preclude positive subject responses to gene transfer following Ad5 vector administration to parotid glands. However, at least among the subjects treated herein, changes beyond that level likely impede the efficacy of gene transfer.
Finally, we examined supernatants obtained following the above PBMC stimulation using a multiplex assay for a panel of cytokines. We found this assay was unhelpful in distinguishing responders and non-responders, with no consistent patterns seen in each group (Figure 4 and supplementary Figure 3 ). Recently, it has been reported that pre-existing natural immunity to Ad5 (Ad5 seronegative, ≤18 vs titers >200) in HIV-negative volunteers was associated with differences in T-cell reactivity, measured as cytokine profiles in PBMCs stimulated ex vivo with an empty Ad5 vector (Pine et al., 2011) . Herein, six subjects exhibited NAb titers ≤18. All (25, 40, 73, 116, all non-responders; and 99, 50 both responders) generally showed few changes in their ex vivo PMBC cytokine profile ( Figure   4 ). Conversely, four subjects with very high NAb titers (≥1024; 4 and 105, non-responders; 103 and 118, responders) displayed heterogenous cytokine profiles, with no clear pattern (Figure 4) . In retrospect, instead of determining cytokine profiles ex vivo with Ad5 antigenstimulated PMBCs, it may have been more informative for us to examine saliva directly from the targeted gland for the presence of inflammatory cytokines, since in patients with Sjögren's syndrome, local (salivary) cytokines are elevated significantly when compared to serum levels (Chiappin et al., 2007 , Grisius et al., 1997 .
As noted above, while host defense against adenovirus involves both innate and adaptive immune responses, the predominant response is through innate immunity (Gregory et al., 2011 , Nayak & Herzog, 2010 . Indeed, the multifaceted innate immune response, not adaptive immunity, is generally considered to be the limiting factor in successful Ad vectormediated gene transfer, accounting for as much as 90% of vector clearance within the first 24 hours following intravenous vector administration (Nayak & Herzog, 2010) . Furthermore, macrophages and other phagocytic cells involved in innate responses can directly influence adaptive immune responses, through production of inflammatory cytokines, such as TNFα and IL-6, as well as IL-8, which acts as a major chemoattractant for neutrophils (Gregory et al., 2011) .
In the present study, following vector administration three of the six non-responders (4, 105, 116) showed clear evidence of a significant innate immune response (marked increases above baseline levels of 67 Gallium citrate uptake in the targeted parotid gland at 24 hours; 49%, 29%, 22%, respectively), while at this time point none of the responders showed levels of 67 Gallium citrate uptake >11% above baseline (Baum et al., 2012) . This is consistent with findings following Ad5-mediated salivary gland gene transfer in rodents (Adesanya et al., 1996 , Wang et al., 2000 , and perhaps suggests the need for co-administration of antiinflammatory glucocorticoids in some individuals to ablate this immune reactivity (Seregin et al., 2009) . Indeed, an elevated 67 Ga scan at 24-hours may be the easiest and most costeffective early predictor of a negative response to Ad5-mediated gene transfer in a salivary gland.
In summary, these data represent the first immune reactivity data obtained following Ad5 vector-mediated gene transfer to salivary glands in humans. However, the aggregate results are not surprising, based on previous human studies of both Ad infections and Ad vectormediated gene transfer performed in other tissue targets, including skin and a related epithelial organ, lung (Harvey et al., 2001) . Ad5 Neutralizing antibodies titers for all subjects until Day 42 are represented by blue squares for responders and by orange circles for non-responders. Subjects receiving the first, lowest vector dose (Dose 1) are traced over shown with solid lines; subjects receiving Dose 2 are depicted with dash-gap lines; Dose 3 subjects are shown with square dotted lines and Dose 4 subjects are shown with square dot-gap-dash lines. Two subjects had identical titers and their traces on the figure are superimposed (subjects #40 and # 73 had titers of <1:2 throughout all reported time points). There are no patterns in the change of titers between responders and non-responders for any of the different doses. See Table on for additional information on baseline titers and vector doses. Summary of subjects' characteristics in AdhAQP1 clinical trial 1
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